The present application relates to antibacterial compounds (Fab1 inhibitors) of formula (I)wherein, independently for each occurrence,A is a monocyclic ring of 4-7 atoms containing 0-2 heteroatoms, a bicyclic ring of 8-12 atoms containing 0-4 heteroatoms, or a tricyclic ring of 8-12 atoms containing 0-6 heteroatoms, wherein the rings are independently aliphatic, aromatic, heteroaryl or heterocyclic in nature, the heteroatoms are selected from N, S, or O, and the rings are optionally substituted with one or more substituents selected from the group consisting of C1-4alkyl, OR", CN, OCF3, F, Cl, Br, and I； wherein R" is H, alkyl, aralkyl, or heteroaralkyl；R iswherein, independently for each occurrence,R4 is H, alkyl, aryl, hydroxy substituted alkyl, or -C(O)ONa；R5 is H, alkyl, or aryl；R6 is H, alkyl, or aryl； andL1 is O or H2；or a pharmaceutically acceptable salt thereof.
